{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T23:17:35Z","timestamp":1793661455122,"version":"4.5.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s40257-026-01021-6","type":"journal-article","created":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T17:22:26Z","timestamp":1775755346000},"page":"579-586","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The Impact of GLP-1 Receptor Agonists on Hair: Beneficial Effects or Adverse Outcomes?"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6466-2199","authenticated-orcid":false,"given":"S. Morteza","family":"Seyed Jafari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemma","family":"Caro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shari R.","family":"Lipner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matilde","family":"Iorizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,9]]},"reference":[{"issue":"6","key":"1021_CR1","doi-asserted-by":"publisher","first-page":"2821","DOI":"10.1007\/s12325-021-01710-0","volume":"38","author":"J Ard","year":"2021","unstructured":"Ard J, Fitch A, Fruh S, Herman L. Weight loss and maintenance related to the mechanism of action of Glucagon-like peptide 1 receptor agonists. Adv Ther. 2021;38(6):2821\u201339.","journal-title":"Adv Ther"},{"issue":"5","key":"1021_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/diseases13050127","volume":"13","author":"C Persson","year":"2025","unstructured":"Persson C, Eaton A, Mayrovitz HN. A closer look at the dermatological profile of GLP-1 agonists. Diseases. 2025;13(5):127.","journal-title":"Diseases"},{"issue":"3","key":"1021_CR3","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1007\/s11695-023-06971-y","volume":"34","author":"M Kami\u0144ski","year":"2024","unstructured":"Kami\u0144ski M, Mi\u0119tkiewska-Dolecka M, Kr\u0119gielska-Naro\u017cna M, Bogda\u0144ski P. Popularity of surgical and pharmacological obesity treatment methods searched by Google users: the retrospective analysis of Google Trends statistics in 2004\u20132022. Obes Surg. 2024;34(3):882\u201391.","journal-title":"Obes Surg"},{"issue":"1","key":"1021_CR4","doi-asserted-by":"publisher","DOI":"10.1002\/edm2.462","volume":"7","author":"Z Mariam","year":"2024","unstructured":"Mariam Z, Niazi SK. Glucagon-like peptide agonists: a prospective review. Endocrinol Diabetes Metab Case Rep. 2024;7(1):e462.","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"issue":"11","key":"1021_CR5","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.2337\/dci24-0003","volume":"47","author":"DJ Drucker","year":"2024","unstructured":"Drucker DJ. Efficacy and safety of GLP-1 medicines for type 2 diabetes and obesity. Diabetes Care. 2024;47(11):1873\u201388.","journal-title":"Diabetes Care"},{"issue":"1","key":"1021_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/cells13010065","volume":"13","author":"SS Wilbon","year":"2023","unstructured":"Wilbon SS, Kolonin MG. GLP1 receptor agonists-effects beyond obesity and diabetes. Cells. 2023;13(1):65.","journal-title":"Cells"},{"issue":"1","key":"1021_CR7","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1097\/RHU.0000000000001949","volume":"30","author":"D Karacabeyli","year":"2024","unstructured":"Karacabeyli D, Lacaille D. Glucagon-like peptide 1 receptor agonists in patients with inflammatory arthritis or psoriasis: a scoping review. J Clin Rheumatol. 2024;30(1):26\u201331.","journal-title":"J Clin Rheumatol"},{"issue":"3","key":"1021_CR8","first-page":"202","volume":"11","author":"TD Filippatos","year":"2015","unstructured":"Filippatos TD, Panagiotopoulou TV, Elisaf MS. Adverse effects of GLP-1 receptor agonists. Rev Diabet Stud. 2015;11(3):202.","journal-title":"Rev Diabet Stud"},{"key":"1021_CR9","doi-asserted-by":"publisher","DOI":"10.5812\/jssc-146625","volume":"11","author":"NM George","year":"2024","unstructured":"George NM, Sangolli PM, Thulaseedharan A, Dominic S. Cutaneous adverse drug reactions to antidiabetic medications and medical devices used in management of diabetes mellitus. J Skin Stem Cell. 2024;11:e146625.","journal-title":"J Skin Stem Cell"},{"issue":"8","key":"1021_CR10","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1007\/s13300-021-01113-y","volume":"12","author":"S Kalra","year":"2021","unstructured":"Kalra S, Bhattacharya S, Kapoor N. Contemporary classification of Glucagon-like peptide 1 receptor agonists (GLP1RAs). Diabetes Ther. 2021;12(8):2133\u201347.","journal-title":"Diabetes Ther"},{"issue":"12","key":"1021_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2022.108332","volume":"36","author":"S Tall Bull","year":"2022","unstructured":"Tall Bull S, Nuffer W, Trujillo JM. Tirzepatide: a novel, first-in-class, dual GIP\/GLP-1 receptor agonist. J Diabetes Complicat. 2022;36(12):108332.","journal-title":"J Diabetes Complicat"},{"issue":"2-3","key":"1021_CR12","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.regpep.2006.02.007","volume":"134","author":"JF List","year":"2006","unstructured":"List JF, He H, Habener JF. Glucagon-like peptide-1 receptor and proglucagon expression in mouse skin. Regul Pept. 2006;134(2\u20133):149\u201357.","journal-title":"Regul Pept"},{"issue":"5","key":"1021_CR13","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1159\/000544023","volume":"11","author":"OM Burke","year":"2025","unstructured":"Burke OM, Sa B, Cespedes DA, Tosti A. Dermatologic implications of Glucagon-Like Peptide-1 receptor agonist medications. Skin Appendage Disord. 2025;11(5):416\u201323.","journal-title":"Skin Appendage Disord"},{"issue":"3","key":"1021_CR14","first-page":"42","volume":"18","author":"W Patino","year":"2025","unstructured":"Patino W, Thomas A, Jain S, Del Rosso JQ, Issa NT. A review of Glucagon-like Peptide-1 in dermatology. J Clin Aesthet Dermatol. 2025;18(3):42\u201350.","journal-title":"J Clin Aesthet Dermatol"},{"key":"1021_CR15","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.jdcr.2024.06.001","volume":"50","author":"ER Gordon","year":"2024","unstructured":"Gordon ER, Musleh S, Bordone LA. Treatment of insulin resistance with tirzepatide leading to improvement of hair loss. JAAD Case Rep. 2024;50:123\u20135.","journal-title":"JAAD Case Rep"},{"issue":"3","key":"1021_CR16","doi-asserted-by":"publisher","first-page":"276","DOI":"10.4103\/2229-5178.137776","volume":"5","author":"OA Bakry","year":"2014","unstructured":"Bakry OA, Shoeib MA, El Shafiee MK, Hassan A. Androgenetic alopecia, metabolic syndrome, and insulin resistance: is there any association? A case-control study. Indian Dermatol Online J. 2014;5(3):276\u201381.","journal-title":"Indian Dermatol Online J"},{"issue":"12","key":"1021_CR17","volume":"16","author":"K Morrissette","year":"2024","unstructured":"Morrissette K, Hansen S, Pavlis M, Murray JC. Improvement of recalcitrant Folliculitis Decalvans with tirzepatide: a case report. Cureus. 2024;16(12):e76267.","journal-title":"Cureus"},{"issue":"3","key":"1021_CR18","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/j.jaad.2025.04.058","volume":"93","author":"N Desir","year":"2025","unstructured":"Desir N, Encarnacion IN, Schell N, Anusionwu I, Ogunleye TA, Taylor SC. GLP-1 agonists may modulate treatment efficacy in Central Centrifugal Cicatricial Alopecia. J Am Acad Dermatol. 2025;93(3):771\u20133.","journal-title":"J Am Acad Dermatol"},{"issue":"10403","key":"1021_CR19","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/S0140-6736(23)01185-6","volume":"402","author":"FK Knop","year":"2023","unstructured":"Knop FK, Aroda VR, do Vale RD, Holst-Hansen T, Laursen PN, Rosenstock J, et al. Oral semaglutide 50\u00a0mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;402(10403):705\u201319.","journal-title":"Lancet"},{"issue":"3","key":"1021_CR20","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","volume":"387","author":"AM Jastreboff","year":"2022","unstructured":"Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205\u201316.","journal-title":"N Engl J Med"},{"issue":"14","key":"1021_CR21","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1001\/jama.2021.1831","volume":"325","author":"TA Wadden","year":"2021","unstructured":"Wadden TA, Bailey TS, Billings LK, Davies M, Frias JP, Koroleva A, et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA. 2021;325(14):1403\u201313.","journal-title":"JAMA"},{"issue":"2","key":"1021_CR22","doi-asserted-by":"publisher","first-page":"e153","DOI":"10.1111\/jdv.20197","volume":"39","author":"H Godfrey","year":"2025","unstructured":"Godfrey H, Leibovit-Reiben Z, Jedlowski P, Thiede R. Alopecia associated with the use of semaglutide and tirzepatide: a disproportionality analysis using the FDA adverse event reporting system (FAERS) from 2022 to 2023. J Eur Acad Dermatol Venereol. 2025;39(2):e153\u20134.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"1021_CR23","doi-asserted-by":"publisher","first-page":"3490","DOI":"10.1111\/dom.16376","volume":"27","author":"TH Kim","year":"2025","unstructured":"Kim TH, Lee K, Park S, Oh J, Park J, Jo H, et al. Adverse drug reaction patterns of GLP-1 receptor agonists approved for obesity treatment: disproportionality analysis from global pharmacovigilance database. Diabetes Obes Metab. 2025;27(6):3490\u2013502.","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"1021_CR24","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1007\/s10557-024-07613-w","volume":"39","author":"M Nakhla","year":"2025","unstructured":"Nakhla M, Nair A, Balani P, Ujjawal A, Arun Kumar P, Dasari M, et al. Risk of suicide, hair loss, and aspiration with GLP1-receptor agonists and other diabetic agents: a real-world pharmacovigilance study. Cardiovasc Drugs Ther. 2025;39(6):1331\u201341.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"5","key":"1021_CR25","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/j.jaad.2025.01.046","volume":"92","author":"O Burke","year":"2025","unstructured":"Burke O, Sa B, Cespedes DA, Sechi A, Tosti A. Glucagon-like peptide-1 receptor agonist medications and hair loss: a retrospective cohort study. J Am Acad Dermatol. 2025;92(5):1141\u20133.","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"1021_CR26","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1111\/ijd.17971","volume":"64","author":"A Singal","year":"2025","unstructured":"Singal A, Ong MM, Neubauer Z, Lipner SR. Association between androgenetic alopecia and glucagon-like peptide-1 receptor treatment in type 2 diabetes mellitus patients: a retrospective cohort study. Int J Dermatol. 2025;64(11):2157\u20139.","journal-title":"Int J Dermatol"},{"issue":"3","key":"1021_CR27","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1530\/EC-18-0514","volume":"8","author":"M Jensterle","year":"2019","unstructured":"Jensterle M, Podbregar A, Goricar K, Gregoric N, Janez A. Effects of liraglutide on obesity-associated functional hypogonadism in men. Endocr Connect. 2019;8(3):195\u2013202.","journal-title":"Endocr Connect"},{"issue":"3","key":"1021_CR28","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1111\/exd.12339","volume":"23","author":"R Panchaprateep","year":"2014","unstructured":"Panchaprateep R, Asawanonda P. Insulin-like growth factor-1: roles in androgenetic alopecia. Exp Dermatol. 2014;23(3):216\u20138.","journal-title":"Exp Dermatol"},{"issue":"11","key":"1021_CR29","doi-asserted-by":"publisher","first-page":"3307","DOI":"10.7150\/ijbs.80481","volume":"19","author":"K Li","year":"2023","unstructured":"Li K, Sun Y, Liu S, Zhou Y, Qu Q, Wang G, et al. The AR\/miR-221\/IGF-1 pathway mediates the pathogenesis of androgenetic alopecia. Int J Biol Sci. 2023;19(11):3307\u201323.","journal-title":"Int J Biol Sci"},{"issue":"10","key":"1021_CR30","doi-asserted-by":"publisher","first-page":"7329","DOI":"10.1074\/jbc.M610447200","volume":"282","author":"W Fan","year":"2007","unstructured":"Fan W, Yanase T, Morinaga H, Okabe T, Nomura M, Daitoku H, et al. Insulin-like growth factor 1\/insulin signaling activates androgen signaling through direct interactions of Foxo1 with androgen receptor. J Biol Chem. 2007;282(10):7329\u201338.","journal-title":"J Biol Chem"},{"issue":"6","key":"1021_CR31","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1016\/j.jaad.2025.08.033","volume":"93","author":"ZMMO Neubauer","year":"2025","unstructured":"Neubauer ZMMO, Singal A, Lipner SR. Increased risk of telogen effluvium with tirzepatide compared to other weight loss medications: a retrospective cohort TriNetX database study. J Am Acad Dermatol. 2025;93(6):1612\u20134.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1021_CR32","doi-asserted-by":"publisher","first-page":"413","DOI":"10.36849\/JDD.8605","volume":"24","author":"S Daniel","year":"2025","unstructured":"Daniel S, Waggett S, Lyles E, Sagut P, Shamaei Zadeh P, Marcelletti A, et al. A retrospective comparative analysis of cutaneous adverse reactions in GLP-1 agonist therapies. J Drugs Dermatol. 2025;24(4):413\u20135.","journal-title":"J Drugs Dermatol"},{"issue":"1","key":"1021_CR33","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.jaad.2024.03.021","volume":"91","author":"MM Tran","year":"2024","unstructured":"Tran MM, Mirza FN, Lee AC, Goldbach HS, Libby TJ, Wisco OJ. Dermatologic findings associated with semaglutide use: a scoping review. J Am Acad Dermatol. 2024;91(1):166\u20138.","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"1021_CR34","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1111\/ijd.17246","volume":"63","author":"DD Desai","year":"2024","unstructured":"Desai DD, Sikora M, Nohria A, Bordone L, Caplan AS, Shapiro J, et al. GLP-1 agonists and hair loss: a call for further investigation. Int J Dermatol. 2024;63(9):1128\u201330.","journal-title":"Int J Dermatol"},{"issue":"3","key":"1021_CR35","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.70125","volume":"24","author":"D Haykal","year":"2025","unstructured":"Haykal D. Alopecia and semaglutide: connecting the dots for patient safety. J Cosmet Dermatol. 2025;24(3):e70125.","journal-title":"J Cosmet Dermatol"},{"issue":"2","key":"1021_CR36","doi-asserted-by":"publisher","first-page":"325","DOI":"10.3390\/medicina60020325","volume":"60","author":"K Smolarczyk","year":"2024","unstructured":"Smolarczyk K, Meczekalski B, Rudnicka E, Suchta K, Szeliga A. Association of obesity and bariatric surgery on hair health. Medicina (Kaunas). 2024;60(2):325.","journal-title":"Medicina (Kaunas)"},{"issue":"1","key":"1021_CR37","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1159\/000528083","volume":"16","author":"M Hassapidou","year":"2023","unstructured":"Hassapidou M, Vlassopoulos A, Kalliostra M, Govers E, Mulrooney H, Ells L, et al. European Association for the Study of Obesity position statement on medical nutrition therapy for the management of overweight and obesity in adults developed in collaboration with the European Federation of the Associations of Dietitians. Obes Facts. 2023;16(1):11\u201328.","journal-title":"Obes Facts"},{"issue":"3","key":"1021_CR38","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s12529-010-9092-y","volume":"17","author":"LM Nackers","year":"2010","unstructured":"Nackers LM, Ross KM, Perri MG. The association between rate of initial weight loss and long-term success in obesity treatment: does slow and steady win the race? Int J Behav Med. 2010;17(3):161\u20137.","journal-title":"Int J Behav Med"},{"key":"1021_CR39","doi-asserted-by":"publisher","first-page":"583","DOI":"10.2147\/CCID.S200471","volume":"12","author":"A Rebora","year":"2019","unstructured":"Rebora A. Telogen effluvium: a comprehensive review. Clin Cosmet Investig Dermatol. 2019;12:583\u201390.","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"2","key":"1021_CR40","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1136\/bmjnph-2023-000733","volume":"6","author":"JAD Shand","year":"2023","unstructured":"Shand JAD, Young S, Verster F, Peters C. Pilot study to test the safety, tolerability and feasibility of dulaglutide during a low-energy diet for weight loss and improved glycaemic control. BMJ Nutr Prev Health. 2023;6(2):341\u20136.","journal-title":"BMJ Nutr Prev Health"},{"key":"1021_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102661","volume":"73","author":"H Moll","year":"2024","unstructured":"Moll H, Frey E, Gerber P, Geidl B, Kaufmann M, Braun J, et al. GLP-1 receptor agonists for weight reduction in people living with obesity but without diabetes: a living benefit-harm modelling study. EClinicalMedicine. 2024;73:102661.","journal-title":"EClinicalMedicine"},{"issue":"11","key":"1021_CR42","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.1038\/s41591-023-02597-w","volume":"29","author":"TA Wadden","year":"2023","unstructured":"Wadden TA, Chao AM, Machineni S, Kushner R, Ard J, Srivastava G, et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. Nat Med. 2023;29(11):2909\u201318.","journal-title":"Nat Med"},{"issue":"9","key":"1021_CR43","volume":"17","author":"OA Alsuwailem","year":"2025","unstructured":"Alsuwailem OA, Alanazi R, Almutairi HM, Asiree RH, Almutairi W, Almutairi TM, et al. Hair loss associated with Glucagon-Like Peptide-1 (GLP-1) receptor agonist use: a systematic review. Cureus. 2025;17(9):e92454.","journal-title":"Cureus"},{"issue":"2","key":"1021_CR44","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1111\/jdv.20512","volume":"39","author":"MG Buontempo","year":"2025","unstructured":"Buontempo MG, Santos BT. Exploring the hair loss risk in Glucagon-Like Peptide-1 agonists: emerging concerns and clinical implications. J Eur Acad Dermatol Venereol. 2025;39(2):263\u20134.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1021_CR45","doi-asserted-by":"publisher","unstructured":"Camino-Salvador JM, Rodr\u00edguez-Cuadrado FJ, Pinto-Pulido EL, Fern\u00e1ndez-Parrado M. Glucagon-like peptide-1 receptor agonists and hair loss: an emerging clinical concern. J Eur Acad Dermatol Venereol. 2025. https:\/\/doi.org\/10.1111\/jdv.70088. (Online ahead of print).","DOI":"10.1111\/jdv.70088"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-026-01021-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-026-01021-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-026-01021-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T21:02:11Z","timestamp":1792875731000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-026-01021-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,9]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["1021"],"URL":"https:\/\/doi.org\/10.1007\/s40257-026-01021-6","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,9]]},"assertion":[{"value":"8 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article was originally published under the subscription model but it is now published under an Open Access license.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"None.","order":1,"name":"Ethics","label":"Conflicts of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.","order":5,"name":"Ethics","label":"Availability of Data and Material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Conceptualization\u2014M.I., S.M.S.J.; investigation\u2014all authors; project administration\/supervision\u2014M.I., S.R.L.; writing\u2014original draft\u2014M.I., G.C., S.M.S.J.; writing\u2014review and editing\u2014all authors. All authors read and approved the final manuscript.","order":7,"name":"Ethics","label":"Authors Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}